Holen Sie sich die Stockscreener-App
4.39
5.59%
-0.26
Vorhandelsmarkt:
4.41
0.02
+0.46%
Schlusskurs vom Vortag:
$4.65
Offen:
$4.56
24-Stunden-Volumen:
49,906
Relative Volume:
0.02
Marktkapitalisierung:
$6.55M
Einnahmen:
$8.62M
Nettoeinkommen (Verlust:
$-6.15M
KGV:
-0.398
EPS:
-11.03
Netto-Cashflow:
$-5.32M
1W Leistung:
-14.42%
1M Leistung:
+59.46%
6M Leistung:
+2.09%
1J Leistung:
-28.41%
1-Tages-Spanne:
$4.34
$4.56
1-Wochen-Bereich:
$4.1744
$5.2984
52-Wochen-Spanne:
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Firmenname
Evoke Pharma Inc
Sektor
Telefon
858-345-1494
Adresse
420 STEVENS AVENUE, SOLANA BEACH, CA
Vergleichen Sie EVOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
4.39 | 7.66M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | Fortgesetzt | FBR & Co. | Buy |
| 2017-03-16 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-01-30 | Hochstufung | Laidlaw | Neutral → Buy |
| 2017-01-05 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | Bestätigt | Rodman & Renshaw | Neutral |
| 2016-07-19 | Bestätigt | FBR Capital | Outperform |
| 2016-07-19 | Herabstufung | Noble Financial | Buy → Hold |
| 2016-07-18 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | Eingeleitet | Northland Capital | Outperform |
| 2016-03-14 | Bestätigt | Ascendiant Capital Markets | Buy |
| 2016-02-17 | Fortgesetzt | FBR Capital | Outperform |
| 2014-12-03 | Bestätigt | MLV & Co | Buy |
| 2014-11-07 | Eingeleitet | MLV & Co | Buy |
| 2014-04-22 | Eingeleitet | Laidlaw | Buy |
| 2013-11-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten
Evoke Pharma Inc. Stock Analysis and ForecastMassive wealth growth - jammulinksnews.com
What analysts say about Evoke Pharma Inc. stockTriple-digit profit margins - jammulinksnews.com
Is Evoke Pharma Inc. a good long term investmentRapid wealth creation - jammulinksnews.com
What drives Evoke Pharma Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
What drives bioAffinity Technologies Inc. Equity Warrant stock priceRemarkable growth - Autocar Professional
What analysts say about PSQH stockFree Stock Market Forecast Reports - Jammu Links News
MGP Ingredients Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI - MSN
Why did EVOK's Q4 2024 earnings beat forecasts? - AInvest
How Evoke Pharma Inc. stock performs during market volatilityReal Time Breakout Tracking - Newser
Why Evoke Pharma Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser
What makes Evoke Pharma Inc. stock price move sharplyVerified Chart Patterns - Newser
Small Cap Stocks Worth Watching – July 9th - Defense World
Promising Pharmaceutical Stocks To Watch Now – July 9th - Defense World
Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In - NewsBreak: Local News & Alerts
Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug - Mugglehead Magazine
Evoke Pharma receives patent allowance for gastroparesis nasal spray By Investing.com - Investing.com South Africa
Evoke Pharma (EVOK) Soars 162.78% on Patent Extension - AInvest
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
Evoke Pharma shares surge 24.57% intraday after receiving Notice of Allowance for U.S. patent application for GIMOTI®. - AInvest
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Evoke Pharma Shares Soar After Patent Allowance for Gastroparesis Treatment - MarketScreener
Evoke Pharma (EVOK) Stock Soars Following Positive Patent News - Stocks Telegraph
Evoke Pharma: Is the Bounce Back Real? - StocksToTrade
EVOK Stock: Boom or Bust? - timothysykes.com
Evoke Pharma (EVOK) Secures New Patent Approval for GIMOTI | EVO - GuruFocus
Evoke Pharma stock soars after receiving patent allowance for GIMOTI By Investing.com - Investing.com South Africa
Evoke Pharma stock soars after receiving patent allowance for GIMOTI - Investing.com
Finanzdaten der Evoke Pharma Inc-Aktie (EVOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):